Vitamin D metabolism and signaling in the immune system

  • John H. White


Vitamin D has emerged as a pleiotropic regulator of human physiology, and recent work has revealed that it has several roles in control of human immune system function. Vitamin D was originally characterized for its role in calcium homeostasis, and the active form, 1,25-dihydroxyvitamin D (1,25D), can be produced in the kidney by 1α-hydroxylation of circulating 25-hydroxyvitamin D catalyzed by the enzyme CYP27B1. Renal CYP27B1 expression is regulated by calcium regulatory inputs, and 1,25D produced in the kidney was thought to function largely as an endocrine hormone. However, it is now clear that CYP27B1 is expressed in numerous tissues, and that 1,25D acts at several sites in the body in an intracrine or paracrine manner. In particular, both CYP27B1 and the vitamin D receptor (VDR) are expressed in several cell types in the immune system, where CYP27B1 production is controlled by a number of immune-specific inputs. Recent research has opened several windows on the molecular mechanisms by which 1,25D signaling regulates both innate and adaptive immune responses in humans. Moreover, intervention trials are beginning to provide evidence that vitamin D supplementation can bolster clinical responses to infection. This review will discuss recent developments in our understanding of how immune signaling controls local vitamin D metabolism and how, in turn, the 1,25D-bound VDR modulates immune system function. A particular emphasis will be placed on the interplay between vitamin D signaling and signaling through different classes of pattern recognition receptors in the production of antimicrobial peptides during innate immune responses to microbial infection.


Vitamin D CYP27B1 Vitamin D receptor Innate immunity Adaptive immunity Macrophages Pattern recognition receptors Antimicrobial peptides 


  1. 1.
    Tavera-Mendoza L, White JH. Cell defenses and the sunshine vitamin. Sci Am. 2007;297:62–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Cheng JB, Levine MA, Bell NH, et al. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A. 2004;101:7711–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Holick MF. Vitamin D deficiency. New Engl J Med. 2007;357:266–81.PubMedCrossRefGoogle Scholar
  4. 4.
    Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci. 2004;29:664–73.PubMedCrossRefGoogle Scholar
  5. 5.
    Shinkyo R, Sakaki T, Kamakura M, et al. Metabolism of vitamin D by human microsomal CYP2R1. Biochem Biophys Res Commun. 2004;324:451–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 2001;86:888–94.PubMedCrossRefGoogle Scholar
  7. 7.
    Hewison M, Burke F, Evans KN, et al. Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. J Ster Biochem Mol Biol. 2007;103:316–21.CrossRefGoogle Scholar
  8. 8.
    Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet. 1998;351:805–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18–28.PubMedGoogle Scholar
  10. 10.
    Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81:353–73.PubMedCrossRefGoogle Scholar
  11. 11.
    Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7:439–43.PubMedCrossRefGoogle Scholar
  12. 12.
    Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. New Engl J Med. 1998;338:777–83.PubMedCrossRefGoogle Scholar
  13. 13.
    Holick MF, Siris ES, Binkley N, et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005;90:3215–24.PubMedCrossRefGoogle Scholar
  14. 14.
    Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Heaney RP, Holick MF. Why the IOM recommendations for vitamin D are deficient. J Bone Miner Res. 2011;26:455–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Slomski A. IOM endorses vitamin D, calcium only for bone health, dispels deficiency claims. JAMA. 2011;305:455–7.Google Scholar
  17. 17.
    Chawla A, Repa J, Evans RM, et al. Nuclear receptors and lipid physiology: opening the X-files. Science. 2001;294:1866–70.PubMedCrossRefGoogle Scholar
  18. 18.
    Lin R, White JH. The pleiotropic actions of vitamin D. BioEssays. 2004;26:21–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Lin R, Nagai Y, Sladek R, et al. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 signaling on cell proliferation, differentiation and immune system regulation. Mol Endocrinol. 2002;16:1243–56.PubMedCrossRefGoogle Scholar
  20. 20.
    Wang TT, Tavera-Mendoza L, Laperriere D, et al. Large-scale in silico and microarray-based genomic screening of 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005;19:2685–95.PubMedCrossRefGoogle Scholar
  21. 21.
    Matthews D, LaPorta E, Zinser GM, et al. Genomic vitamin D signaling in breast cancer: insights from animal models and human cells. J Steroid Biochem Mol Biol. 2010;121:362–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Rochel N, Wurtz JM, Mitschler A, et al. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell. 2000;5:173–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Drocourt L, Ourlin JC, Pascussi JM, et al. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem. 2002;277:25125–32.PubMedCrossRefGoogle Scholar
  24. 24.
    Thompson PD, Jurutka PW, Whitfield GK, et al. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem Biophys Res Comm. 2002;299:730–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Thummel KE, Brimer C, Yasuda K, et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxyvitamin D3. Mol Pharmacol. 2001;60:1399–406.PubMedGoogle Scholar
  26. 26.
    Tavera-Mendoza L, Wang TT, Lallemant B, et al. Convergence of vitamin D and retinoic acid signaling at a common hormone response element. EMBO Rep. 2006;7:180–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Matilainen JM, Husso T, Toropainen S, et al. Primary effect of 1α,25(OH)2D3 on IL-10 expression in monocytes is short-term down-regulation. Biochim Biophys Acta. 2010;1803:1276–86.PubMedCrossRefGoogle Scholar
  28. 28.
    Dilworth FJ, Chambon P. Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription. Oncogene. 2001;20:3047–54.PubMedCrossRefGoogle Scholar
  29. 29.
    McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell. 2002;108:465–74.PubMedCrossRefGoogle Scholar
  30. 30.
    Kim S, Yamazaki M, Zella LA, et al. Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol Cell Biol. 2006;26:6469–86.PubMedCrossRefGoogle Scholar
  31. 31.
    Meyer MB, Goetsch PD, Pike JW. A downstream intergenic cluster of regulatory enhancers contributes to the induction of CYP24A1 expression by 1alpha,25-dihydroxyvitamin D3. J Biol Chem. 2010;285:15599–610.PubMedCrossRefGoogle Scholar
  32. 32.
    Takeuchi A, Reddy G, Kobayashi T, et al. Nuclear factor of activated T cells (NFAT) as a molecular target for 1,25-dihydroxyvitamin D3-mediated effects. J Immunol. 1998;160:209–18.PubMedGoogle Scholar
  33. 33.
    An B-S, Tavera-Mendoza LE, Dimitrov V, et al. Stimulation of SIRT1-regulated FoxO protein function by the ligand-bound vitamin D receptor. Mol Cell Biol. 2010;30:4890–900.PubMedCrossRefGoogle Scholar
  34. 34.
    Masten AR. Sunlight in tuberculosis. Chest. 1935;1:8–23.CrossRefGoogle Scholar
  35. 35.
    Guy RA. The history of cod liver oil as a remedy. Am J Dis Child. 1923;26:112–6.Google Scholar
  36. 36.
    Grad R. Cod and the consumptive: a brief history of cod-liver oil in the treatment of pulmonary tuberculosis. Pharm Hist. 2004;46:106–20.PubMedGoogle Scholar
  37. 37.
    Martineau AR, Honecker FU, Wilkinson RJ, Griffiths CJ. Vitamin D in the treatment of pulmonary tuberculosis. J Ster Biochem Mol Biol. 2007;103:793–8.CrossRefGoogle Scholar
  38. 38.
    Rook GA, Steele J, Fraher L, Barker S, Karmali R, O'Riordan J, et al. Vitamin D3, interferon, and control of proliferation of mycobacterium tuberculosis by human monocytes. Immunol. 1986;57:159–63.Google Scholar
  39. 39.
    White JH. Vitamin D signaling, infectious diseases, and regulation of innate immunity. Infect Immun. 2008;76:3837–43.PubMedCrossRefGoogle Scholar
  40. 40.
    Martineau AR, Timms PM, Bothamley GH, et al. High-dose vitamin D-3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet. 2011;377:242–50.PubMedCrossRefGoogle Scholar
  41. 41.
    Urashima M, Segawa T, Okazaki M, et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr. 2010;91:1255–60.PubMedCrossRefGoogle Scholar
  42. 42.
    Ichinohe T, Pang IK, Kumamoto Y, et al. Micobiota regulates immune defense against respiratory tract influenza A virus infection. Proc Nat Acad Sci U S A. 2011;108:5354–9.CrossRefGoogle Scholar
  43. 43.
    Bhalla AK, Amento EP, Serog B, Glimcher LH. 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol. 1984;133:1748–54.PubMedGoogle Scholar
  44. 44.
    Brennan A, Katz DR, Nunn JD, Barker S, et al. Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. Immunol. 1987;61:457–61.Google Scholar
  45. 45.
    Adorini L, Penna G. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Human Immunol. 2009;70:345–52.CrossRefGoogle Scholar
  46. 46.
    Baeke F, Takiishi T, Korf H, et al. Vitamin D: modulator of the immune system. Curr Opin Pharmacol. 2010;10:482–96.PubMedCrossRefGoogle Scholar
  47. 47.
    Von Essen MR, Kongsbak M, Schjerling P, et al. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol. 2010;11:344–9.CrossRefGoogle Scholar
  48. 48.
    Gorman S, Judge MA, Hart PH. Immune-modifying properties of topical vitamin D: focus on dendritic cell and T cells. J Ster Biochem Mol Biol. 2010;121:247–9.CrossRefGoogle Scholar
  49. 49.
    Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol. 2005;5:699–711.PubMedCrossRefGoogle Scholar
  50. 50.
    Prinz JC. From bench to bedside—translational research in psoriasis. J Eur Acad Dermatol Vernerol. 2010;24:1–4.CrossRefGoogle Scholar
  51. 51.
    Solomon AJ, Whitham RH. Curr Neurol Neurosci Rep. 2010;10:389–96.PubMedCrossRefGoogle Scholar
  52. 52.
    Hypponen E, Laara E, Reunanen E, et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 2001;358:1500–3.PubMedCrossRefGoogle Scholar
  53. 53.
    Jeffery LE, Burke F, Mura M, et al. 1,25-dihydroxyvitamin D-3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol. 2009;183:5458–67.PubMedCrossRefGoogle Scholar
  54. 54.
    Oberg F, Botlin J, Nilsson K. Functional antagonisms between vitamin-D3 and retinoic acid in the regulation of CD14 and CD23 expression during monocytic differentiation of U-937 cells. J Immunol. 1993;150:3487–95.PubMedGoogle Scholar
  55. 55.
    Wang TT, Nestel F, Bourdeau V, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173:2909–12.PubMedGoogle Scholar
  56. 56.
    Hancock REW, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006;24:1551–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Doss M, White MR, Tecle T, Hartshorn KL. Human defensins and LL-37 in mucosal immunity. J Leuk Biol. 2010;87:79–92.CrossRefGoogle Scholar
  58. 58.
    Liu PT, Krutzik SR, Modlin RL. Therapeutic implications of the TLR and VDR partnership. Trends Mol Med. 2007;13:117–24.PubMedCrossRefGoogle Scholar
  59. 59.
    Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D-3. FASEB J. 2005;19:1067–77.PubMedCrossRefGoogle Scholar
  60. 60.
    Liu PT, Stenger S, Li HY, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770–3.PubMedCrossRefGoogle Scholar
  61. 61.
    Weber G, Heilborn JD, Chamorro Jimenez CI, et al. Vitamin D induces the antimicrobial protein hCAP18 in human skin. J Invest Dermatol. 2005;124:1080–2.PubMedCrossRefGoogle Scholar
  62. 62.
    White JH. Vitamin D as an inducer of cathelicidin antimicrobial peptide expression: past, present and future. J Ster Biochem Mol Biol. 2010;121:234–8.CrossRefGoogle Scholar
  63. 63.
    D'Aldebert E, Biyeyeme Bi Mve MJ, Mergey M, et al. Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterol. 2009;136:1435–43.CrossRefGoogle Scholar
  64. 64.
    Makishima M, Lu TT, Xie W, et al. Vitamin D receptor as an intestinal bile acid sensor. Science. 2002;296:1313–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Gombart AF, Saito T, Koeffler HP. Exaptation of an ancient Alu short interspersed element provides a highly conserved vitamin D-mediated innate immune response in humans and primates. BMC Genomics. 2009;10:321.PubMedCrossRefGoogle Scholar
  66. 66.
    Liu PT, Schenk M, Walker VP, et al. Convergence of IL-1 beta and VDR Activation Pathways in Human TLR2/1-Induced Antimicrobial Responses. PLoS ONE. 2009;4:e5810.PubMedCrossRefGoogle Scholar
  67. 67.
    Wang TT, Dabbas B, Laperriere D, et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-beta defensin 2 innate immune pathway defective in Crohn’s disease. J Biol Chem. 2010;285:2227–31.PubMedCrossRefGoogle Scholar
  68. 68.
    Voss E, Wehkamp J, Wehkamp K, et al. NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem. 2006;281:2005–11.PubMedCrossRefGoogle Scholar
  69. 69.
    Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8:458–66.PubMedCrossRefGoogle Scholar
  70. 70.
    Fellermann K, Stange DE, Schaeffeler E, et al. Am J Hum Genet. 2006;79:439–48.PubMedCrossRefGoogle Scholar
  71. 71.
    Coulombe F, Behr MA. Crohn’s disease as an immune deficiency? Lancet. 2009;374:769–70.PubMedCrossRefGoogle Scholar
  72. 72.
    Smith AM, Rahman FZ, Bu’Hussain H, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn’s disease. J Exp Med. 2009;206:1883–97.PubMedCrossRefGoogle Scholar
  73. 73.
    Marks DJB, Rahman FZ, Sewell GW, et al. Crohn’s disease: an immune deficiency state. Clin Rev Allergy Immunol. 2010;38:20–31.PubMedCrossRefGoogle Scholar
  74. 74.
    Lim W-C, Hanauer SB, Li YC. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:308–15.PubMedCrossRefGoogle Scholar
  75. 75.
    Loftus Jr EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterol. 2004;126:1504–17.CrossRefGoogle Scholar
  76. 76.
    Zeng L, Anderson FH. Seasonal change in the exacerbations of Crohn’s disease. Scand J Gastroenterol. 1996;31:79–82.PubMedCrossRefGoogle Scholar
  77. 77.
    Lewis JD, Aberra FN, Lichtenstein GR, et al. Seasonal variation in flares of inflammatory bowel disease. Gastroenterol. 2004;126:665–73.CrossRefGoogle Scholar
  78. 78.
    Aratari A, Papi C, Galletti B, et al. Seasonal variations in onset of symptoms in Crohn’s disease. Dig Liver Dis. 2006;38:319–23.PubMedCrossRefGoogle Scholar
  79. 79.
    Simmons JD, Mullighan C, Welsh KL, Jelwell DP. Vitamin D receptor gene polymorphism: association with Crohn’s disease susceptibility. Gut. 2000;47:211–4.PubMedCrossRefGoogle Scholar
  80. 80.
    Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin N Am. 2010;39:365–79.CrossRefGoogle Scholar
  81. 81.
    Kreutz M, Andreesen R, Krause SW, et al. 1,25-dihydroxyvitamin-D3 production and vitamin-D3 receptor expression are developmentally regulated during differentiation of human monocytes into macrophages. Blood. 1990;76:2457–61.PubMedGoogle Scholar
  82. 82.
    Hewison M, Freeman L, Hughes SV, et al. Differential regulation of the vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol. 2003;170:5382–90.PubMedGoogle Scholar
  83. 83.
    Burke RR, Rybicki BA, Rao DS. Calcium and vitamin D in sarcoidosis: how to assess and manage. Sem Resp Crit Care. 2010;31:474–84.CrossRefGoogle Scholar
  84. 84.
    Stoffels K, Overbergh L, Giulietti A, et al. Immune regulation of 25-hydroxyvitamin-D-3-1 alpha-hydroxylase in human monocytes. J Bone Min Res. 2006;21:37–47.CrossRefGoogle Scholar
  85. 85.
    Evans KN, Taylor H, Zehnder D, et al. Increased expression of 25-hydroxyvitamin D-1 alpha-hydroxylase in dysgerminomas—a novel form of humoral hypercalcemia of malignancy. Am J Pathol. 2004;165:807–13.PubMedCrossRefGoogle Scholar
  86. 86.
    Evans KN, Nguyen L, Chan J, et al. Effects of 25-hydroxyvitamin D-3 and 1,25-dihydroxyvitamin D-3 on cytokine production by human decidual cells. Biol Reprod. 2006;75:816–22.PubMedCrossRefGoogle Scholar
  87. 87.
    Nesby-O'Dell S, Scanlon KS, Cogswell ME, et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: Third National Health and Nutrition Examination Survey, 1988–1994. Am J Clin Nutr. 2002;76:187–92.PubMedGoogle Scholar
  88. 88.
    Stead WW, Senner JW, Reddick WT, Lofgren JP. Racial differences in sensitivity to infection by mycobacterium tuberculosis. N Engl J Med. 1990;322:422–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Krutzik SR, Hewison M, Liu PT, et al. IL-15 links TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. J Immunol. 2008;181:7115–20.PubMedGoogle Scholar
  90. 90.
    Edfeldt K, Liu PT, Chun R, et al. T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. Proc Nat Acad Sci U S A. 2010;107:22593–8.CrossRefGoogle Scholar
  91. 91.
    Akira S. Innate immunity to pathogens: diversity in receptors for microbial recognition. Immunol Rev. 2009;227:5–8.PubMedCrossRefGoogle Scholar
  92. 92.
    Irazoqui JE, Urbach JM, Ausubel FM. Evolution of host innate defence: insights from caenorhabditis elegans and primitive invertebrates. Nat Rev Immunol. 2010;10:47–58.PubMedCrossRefGoogle Scholar
  93. 93.
    Patil A, Hughes AL, Zhang G. Rapid evolution and diversification of mammalian α-defensins as revealed by comparative analysis of rodent and primate genomes. Physiol Genom. 2004;20:1–11.CrossRefGoogle Scholar
  94. 94.
    Zanetti M. Cathelicidins: multifunctional peptides of the innate immunity. J Leuk Biol. 2004;75:39–48.CrossRefGoogle Scholar
  95. 95.
    Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Comm. 2009;388:621–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Physiology, McGill UniversityMontrealCanada

Personalised recommendations